Intech Investment Management LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the 3rd quarter, Holdings Channel reports. The firm purchased 15,214 shares of the medical research company’s stock, valued at approximately $4,488,000.
Several other hedge funds also recently bought and sold shares of the stock. North Dakota State Investment Board lifted its stake in shares of Charles River Laboratories International by 2.7% during the third quarter. North Dakota State Investment Board now owns 1,489 shares of the medical research company’s stock valued at $439,000 after buying an additional 39 shares during the period. Physician Wealth Advisors Inc. grew its stake in Charles River Laboratories International by 127.9% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock worth $29,000 after acquiring an additional 55 shares during the period. Activest Wealth Management grew its stake in Charles River Laboratories International by 25.9% in the 3rd quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after acquiring an additional 57 shares during the period. Choreo LLC raised its holdings in Charles River Laboratories International by 2.8% in the 3rd quarter. Choreo LLC now owns 2,165 shares of the medical research company’s stock valued at $639,000 after acquiring an additional 59 shares during the last quarter. Finally, Empirical Finance LLC raised its holdings in Charles River Laboratories International by 4.4% in the 2nd quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company’s stock valued at $333,000 after acquiring an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.
Analysts Set New Price Targets
CRL has been the topic of a number of recent analyst reports. Jefferies Financial Group increased their price target on Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a research note on Monday, September 28th. Wall Street Zen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Piper Sandler set a $300.00 price objective on Charles River Laboratories International in a research report on Monday, August 10th. Robert W. Baird upped their target price on Charles River Laboratories International from $291.00 to $334.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. Finally, Mizuho increased their target price on Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a research report on Friday, September 25th. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $311.67.
View Our Latest Stock Report on Charles River Laboratories International
Charles River Laboratories International Price Performance
Charles River Laboratories International stock opened at $333.47 on Thursday. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $379.63. The firm has a 50 day moving average price of $314.26 and a 200 day moving average price of $230.05. The company has a market cap of $15.98 billion, a price-to-earnings ratio of 366.45, a PEG ratio of 3.00 and a beta of 1.36. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.12 and a current ratio of 1.41.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping the consensus estimate of $2.97 by $0.12. The firm had revenue of $982.73 million during the quarter, compared to analyst estimates of $960.36 million. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. Charles River Laboratories International’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.43 earnings per share. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current year.
Insider Buying and Selling at Charles River Laboratories International
In related news, EVP Shannon M. Parisotto sold 2,156 shares of the stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,655,578.87. This trade represents a 30.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 24,042 shares of Charles River Laboratories International stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total value of $8,414,700.00. Following the completion of the transaction, the director owned 31,596 shares in the company, valued at $11,058,600. The trade was a 43.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 60,740 shares of company stock valued at $19,528,128 over the last three months. Corporate insiders own 1.30% of the company’s stock.
Charles River Laboratories International Company Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
See Also
- Five stocks we like better than Charles River Laboratories International
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
